{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:44:35Z","timestamp":1769085875656,"version":"3.49.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Astra Zeneca"},{"name":"Phenox"},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Union Framework 7"},{"DOI":"10.13039\/501100008732","name":"EVER Neuro Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008732","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008894","name":"Stryker","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008894","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/501100023867","name":"Swedish Stroke Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023867","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002736","name":"Covidien","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002736","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011727","name":"Stockholm l\u00e4ns landsting","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011727","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018944","name":"Grupo Ferrer Internacional, S.A","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018944","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Union Public Health Authority"},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Astra Zeneca"},{"name":"Phenox"},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union Framework 7"},{"DOI":"10.13039\/501100008732","name":"EVER Neuro Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008894","name":"Stryker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008894","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023867","name":"Swedish Stroke Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002736","name":"Covidien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011727","name":"Stockholm l\u00e4ns landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018944","name":"Grupo Ferrer Internacional, S.A","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018944","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union Public Health Authority"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Data is limited on the safety of early initiation of direct oral anticoagulation (DOAC) treatment after acute ischemic stroke (AIS) receiving reperfusion therapy in patients with atrial fibrillation (AF). We investigated the timing of DOAC initiation and its association with safety and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We included AIS patients receiving reperfusion therapy with AF diagnosis (prevalent or new) registered in the Safe Implementation of Treatments in Stroke international registry during 2013\u20132024. Safety outcomes were hemorrhage and death. Secondary outcomes were recurrent AIS, any embolism and functional independence (modified Rankin Scale [mRS] 0\u20132) at 3\u2009months. We performed descriptive statistics and multivariable analysis for DOAC initiation time as an ordinal variable (0\u20133, 4\u20137, and 8\u2013100\u2009days after stroke onset) and its association with outcomes. Explorative analyses were performed to investigate factors associated with DOAC initiation time, as a continuous or ordinal variable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 13,389 patients had data on DOAC initiation time, and 7861 patients had new event data by 3-month follow-up. We observed 0.1% intracranial hemorrhage, 0.4% major extracranial hemorrhage, 1.1% recurrent ischemic stroke, and 0.2% systemic embolism. At 3\u2009months, 4.8% patients had died, and functional independence was seen in 60.9%. In multivariable analyses, DOAC initiation after stroke onset was not associated with any outcomes. Higher 24\u2009h NIHSS and lower pre-stroke mRS score were associated with delayed DOAC initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DOAC initiation time was not associated with any outcomes in AIS patients who received reperfusion therapy. Severe stroke symptoms at 24\u2009h were associated with delayed DOAC initiation. The low incidence of safety outcomes and missing data in this study should lead to cautious interpretations of these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23969873251325978","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T02:55:48Z","timestamp":1742007348000},"page":"988-994","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Initiation of direct oral anticoagulation after reperfusion therapy in ischemic stroke in clinical practice: Results from Sits-International Stroke Registry"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5606-3311","authenticated-orcid":false,"given":"Malin","family":"S\u00e4flund","sequence":"first","affiliation":[{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden 1"},{"name":"Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2868-127X","authenticated-orcid":false,"given":"Marius","family":"Matusevicius","sequence":"additional","affiliation":[{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden 1"},{"name":"Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose A","family":"Egido","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Clinico Universitario San Carlos, Madrid, Spain 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Ferro","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal 4"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janika","family":"K\u00f5rv","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia 5"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Melis","sequence":"additional","affiliation":[{"name":"SC Neurologia e Stroke Unit, Azienda Ospedaliera G.Brotzu, Cagliari, Italy 6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Peeters","sequence":"additional","affiliation":[{"name":"Department of Neurology, Cliniques universitaires Saint-Luc, Bruxelles, Belgium 7"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Petruzzellis","sequence":"additional","affiliation":[{"name":"Stroke Unit, AOU Consorziale Policlinico, University of Bari, Bari, Italy 8"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8059-4192","authenticated-orcid":false,"given":"Viiu-Marika","family":"Rand","sequence":"additional","affiliation":[{"name":"Department of Neurology, North Estonia Medical Centre, Tallin, Estonia 9"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandras","family":"Vilionskis","sequence":"additional","affiliation":[{"name":"Stroke Center, Clinic of Neurology and Neurosurgery, Vilnius University, Vilnius, Lithuania 10"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Melancia","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio de Lisboa Central, Stroke Center, Lisbon, Portugal 11"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6702-7924","authenticated-orcid":false,"given":"Diana","family":"Aguiar de Sousa","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio de Lisboa Central, Stroke Center, Lisbon, Portugal 11"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael V","family":"Mazya","sequence":"additional","affiliation":[{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden 1"},{"name":"Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago","family":"Moreira","sequence":"additional","affiliation":[{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden 1"},{"name":"Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niaz","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden 1"},{"name":"Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden 2"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"2026012115063690300_bibr1-23969873251325978","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2026012115063690300_bibr2-23969873251325978","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012115063690300_bibr3-23969873251325978","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012115063690300_bibr4-23969873251325978","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012115063690300_bibr5-23969873251325978","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(00)02085-7","article-title":"Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST study group. Heparin in acute embolic stroke trial","volume":"355","author":"Berge","year":"2000","journal-title":"Lancet"},{"key":"2026012115063690300_bibr6-23969873251325978","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2026012115063690300_bibr7-23969873251325978","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1161\/CIRCULATIONAHA.115.015484","article-title":"Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome","volume":"132","author":"Seiffge","year":"2015","journal-title":"Circulation"},{"key":"2026012115063690300_bibr8-23969873251325978","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.122.060666","article-title":"Early versus delayed non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation (TIMING): a registry-based randomized controlled noninferiority study","volume":"146","author":"Oldgren","year":"2022","journal-title":"Circulation"},{"key":"2026012115063690300_bibr9-23969873251325978","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2303048","article-title":"Early versus later anticoagulation for stroke with atrial fibrillation","volume":"388","author":"Fischer","year":"2023","journal-title":"N Engl J Med"},{"key":"2026012115063690300_bibr10-23969873251325978","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012115063690300_bibr11-23969873251325978","doi-asserted-by":"crossref","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"2026012115063690300_bibr12-23969873251325978","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0140-6736(07)60149-4","article-title":"Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study","volume":"369","author":"Wahlgren","year":"2007","journal-title":"Lancet"},{"key":"2026012115063690300_bibr13-23969873251325978","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1161\/STROKEAHA.109.548602","article-title":"Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from safe implementation of thrombolysis in stroke-international stroke thrombolysis register (SITS-ISTR)","volume":"40","author":"Ahmed","year":"2009","journal-title":"Stroke"},{"key":"2026012115063690300_bibr14-23969873251325978","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"2026012115063690300_bibr15-23969873251325978","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"2026012115063690300_bibr16-23969873251325978","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2026012115063690300_bibr17-23969873251325978","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/STROKEAHA.119.028118","article-title":"Early initiation of direct oral anticoagulants after onset of stroke and short- and long-term outcomes of patients with nonvalvular atrial fibrillation","volume":"51","author":"Mizoguchi","year":"2020","journal-title":"Stroke"},{"key":"2026012115063690300_bibr18-23969873251325978","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/STROKEAHA.121.036695","article-title":"Practical \u201c1-2-3-4-day\u201d rule for starting direct oral anticoagulants after ischemic stroke with atrial fibrillation: Combined Hospital-based Cohort Study","volume":"53","author":"Kimura","year":"2022","journal-title":"Stroke"},{"key":"2026012115063690300_bibr19-23969873251325978","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-037234","article-title":"Dabigatran initiation in patients with non-valvular AF and first acute ischaemic stroke: a retrospective observational study from the SITS registry","volume":"10","author":"Escudero-Martinez","year":"2020","journal-title":"BMJ Open"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23969873251325978","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23969873251325978","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/3\/988\/65866628\/23969873251325978.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/3\/988\/65866628\/23969873251325978.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:08:07Z","timestamp":1769026087000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/10\/3\/988\/8376570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1177\/23969873251325978","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,1]]},"published":{"date-parts":[[2025,9,1]]}}}